Update: Hypogonadotropic hypogonadism in type 2 diabetes and obesity

Journal of Clinical Endocrinology and Metabolism

Volumn 96, Issue 9, 2011, Pages 2643-2651

  Dandona, Paresh ^a,b   Dhindsa, Sandeep ^a  

^a UNIVERSITY AT BUFFALO   (United States)

^b STATE UNIVERSITY OF NEW YORK   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROSTENEDIONE; C REACTIVE PROTEIN; ESTRADIOL; FOLLITROPIN; GONADORELIN; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INTERLEUKIN 1BETA; LUTEINIZING HORMONE; PHOSPHODIESTERASE INHIBITOR; PLACEBO; PROSTATE SPECIFIC ANTIGEN; SEX HORMONE BINDING GLOBULIN; TESTOSTERONE; TUMOR NECROSIS FACTOR ALPHA;

ABDOMINAL OBESITY; ANDROGEN THERAPY; ANEMIA; BODY COMPOSITION; BONE DENSITY; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; DRUG SAFETY; ERECTILE DYSFUNCTION; ESTRADIOL BLOOD LEVEL; GLYCEMIC CONTROL; GONADORELIN RELEASE; HEMATOCRIT; HUMAN; HYPOGONADOTROPIC HYPOGONADISM; HYPOTHALAMUS HYPOPHYSIS GONAD SYSTEM; INSULIN RESISTANCE; INSULIN SENSITIVITY; LOW DRUG DOSE; LUTEINIZING HORMONE RELEASE; MALE SEXUAL DYSFUNCTION; METABOLIC SYNDROME X; MUSCLE STRENGTH; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROSTATE CANCER; REVIEW; SIDE EFFECT; TESTOSTERONE BLOOD LEVEL; WAIST CIRCUMFERENCE;

DIABETES MELLITUS, TYPE 2; HUMANS; HYPOGONADISM; MALE; OBESITY;

EID: 80052530001     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/jc.2010-2724     Document Type: Review

References (71)

1. Dhindsa S., Prabhakar S., Sethi M., Bandyopadhyay A., Chaudhuri A., Dandona P. 2004 Frequent occurrence of hypogonadotropic hypogonadism in type 2 diabetes. J Clin Endocrinol Metab 89:5462- 5468
2. Kapoor D., Aldred H., Clark S., Channer K.S., Jones T.H. 2007 Clinical and biochemical assessment of hypogonadism in men with type 2 diabetes: Correlations with bioavailable testosterone and visceral adiposity. Diabetes Care 30:911-917 (Pubitemid 46556586)
3. Rhoden E.L., Ribeiro E.P., Teloken C., Souto C.A. 2005 Diabetes mellitus is associated with subnormal serum levels of free testosterone in men. BJU Int 96:867-870 (Pubitemid 41391398)
4. Grossmann M., Thomas M.C., Panagiotopoulos S., Sharpe K., Macisaac R.J., Clarke S., Zajac J.D., JerumsG.2008Lowtestosterone levels are common and associated with insulin resistance in men with diabetes. J Clin Endocrinol Metab 93:1834-1840 (Pubitemid 351656526)
5. Corona G., Mannucci E., Petrone L., Ricca V., Balercia G., Mansani R., Chiarini V., Giommi R., Forti G., Maggi M. 2006 Association of hypogonadism and type II diabetes in men attending an outpatient erectile dysfunction clinic. Int J Impot Res 18:190-197 (Pubitemid 43336487)
6. Bhasin S., Cunningham G.R., Hayes F.J., Matsumoto A.M., Snyder P.J., Swerdloff R.S., MontoriV.M.2006 Testosterone therapy in adult men with androgen deficiency syndromes: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab 91:1995-2010 (Pubitemid 43854972)
7. Chandel A., Dhindsa S., Topiwala S., Chaudhuri A., Dandona P. 2008 Testosterone concentration in young patients with diabetes. Diabetes Care 31:2013-2017
8. Dhindsa S., Furlanetto R., Vora M., Chaudhuri A., Ghanim H., Dandona P. 29 June 2011 Low estradiol concentrations in males with subnormal testosterone concentrations and type 2 diabetes. Diabetes Care 10.2337/dc11-0208
9. Tomar R., Dhindsa S., Chaudhuri A., Mohanty P., Garg R., Dandona P. 2006 Contrasting testosterone concentrations in type 1 and type 2 diabetes. Diabetes Care 29:1120-1122 (Pubitemid 44115257)
10. Haffner S.M. 2000 Sex hormones, obesity, fat distribution, type 2 diabetes and insulin resistance: Epidemiological and clinical correlation. Int J Obes Relat Metab Disord 24(Suppl 2):S56-S58 (Pubitemid 30461949)
11. Laaksonen D.E., Niskanen L., Punnonen K., Nyyssönen K., Tuomainen T.P., Salonen R., Rauramaa R., Salonen J.T. 2003 Sex hormones, inflammation and the metabolic syndrome: A populationbased study. Eur J Endocrinol 149:601-608 (Pubitemid 38054707)
12. Kapoor D., Channer K.S., Jones T.H. 2008 Rosiglitazone increases bioactive testosterone and reduces waist circumference in hypogonadal men with type 2 diabetes. Diab Vasc Dis Res 5:135-137 (Pubitemid 351839286)
13. Dhindsa S., Miller M.G., McWhirter C.L., Mager D.E., Ghanim H., Chaudhuri A., Dandona P. 2010 Testosterone concentrations in diabetic and nondiabetic obese men. Diabetes Care 33:1186-1192
14. Pitteloud N., Dwyer A.A., DeCruz S., Lee H., Boepple P.A., Crowley Jr W.F., Hayes F.J. 2008 The relative role of gonadal sex steroids and gonadotropin-releasing hormone pulse frequency in the regulation of follicle-stimulating hormone secretion in men. J Clin Endocrinol Metab 93:2686-2692 (Pubitemid 352008537)
15. Tajar A., Forti G., O'Neill T.W., Lee D.M., Silman A.J., Finn J.D., Bartfai G., Boonen S., Casanueva F.F., Giwercman A., Han T.S., Kula K., Labrie F., Lean M.E., Pendleton N., Punab M., Vanderschueren D., Huhtaniemi I.T., Wu F.C. 2010 Characteristics of secondary, primary, and compensated hypogonadism in aging men: Evidence from the European Male Ageing Study. J Clin Endocrinol Metab 95:1810-1818
16. Brüning J.C., Gautam D., Burks D.J., Gillette J., Schubert M., Orban P.C., Klein R., Krone W., Müller-Wieland D., Kahn C.R. 2000 Role of brain insulin receptor in control of body weight and reproduction. Science 289:2122-2125
17. Salvi R., Castillo E., Voirol M.J., Glauser M., Rey J.P., Gaillard R.C., Vollenweider P., Pralong F.P. 2006 Gonadotropin-releasing hormone- expressing neurons immortalized conditionally are activated by insulin: Implication of the mitogen-activated protein kinase pathway. Endocrinology 147:816-826 (Pubitemid 43112999)
18. Gamba M., Pralong F.P. 2006 Control of GnRH neuronal activity by metabolic factors: The role of leptin and insulin. Mol Cell Endocrinol 254-255:133-139 (Pubitemid 44063601)
19. Watanobe H., Hayakawa Y. 2003 Hypothalamic interleukin-1β and tumor necrosis factor-α, but not interleukin-6, mediate the endo-toxin-induced suppression of the reproductive axis in rats. Endocrinology 144:4868-4875 (Pubitemid 37378401)
20. Russell S.H., Small C.J., Stanley S.A., Franks S., Ghatei M.A., Bloom S.R. 2001 The in vitro role of tumour necrosis factor-α and interleukin-6 in the hypothalamic-pituitary gonadal axis. J Neuroendocrinol 13: 296-301 (Pubitemid 32170995)
21. Bhatia V., Chaudhuri A., Tomar R., Dhindsa S., Ghanim H., Dandona P. 2006 Low testosterone and high C-reactive protein concentrations predict low hematocrit in type 2 diabetes. Diabetes Care 29:2289-2294 (Pubitemid 44899867)
22. Vallerie S.N., Furuhashi M., Fucho R., Hotamisligil G.S. 2008 A predominant role for parenchymal c-Jun amino terminal kinase (JNK) in the regulation of systemic insulin sensitivity. PLoS One 3:e3151
23. Dandona P., Aljada A., Bandyopadhyay A. 2004 Inflammation: The link between insulin resistance, obesity and diabetes. Trends Immunol 25:4-7 (Pubitemid 38032801)
24. Ghanim H., Aljada A., Daoud N., Deopurkar R., Chaudhuri A., Dandona P. 2007 Role of inflammatory mediators in the suppression of insulin receptor phosphorylation in circulating mononuclear cells of obese subjects. Diabetologia 50:278-285
25. Pitteloud N., Hardin M., Dwyer A.A., Valassi E., Yialamas M., Elahi D., Hayes F.J. 2005 Increasing insulin resistance is associated with a decrease in Leydig cell testosterone secretion in men. J Clin Endocrinol Metab 90:2636-2641 (Pubitemid 40686302)
26. Oh J.Y., Barrett-Connor E., Wedick N.M., Wingard D.L. 2002 Endogenous sex hormones and the development of type 2 diabetes in older men and women: The Rancho Bernardo study. Diabetes Care 25: 55-60 (Pubitemid 41070783)
27. Haffner S.M., Shaten J., Stern M.P., Smith G.D., Kuller L. 1996 Low levels of sex hormone-binding globulin and testosterone predict the development of non-insulin-dependent diabetes mellitus in men. MRFIT Research Group. Multiple Risk Factor Intervention Trial. Am J Epidemiol 143:889-897 (Pubitemid 26131096)
28. Laaksonen D.E., Niskanen L., Punnonen K., Nyyssönen K., Tuomainen T.P., Valkonen V.P., Salonen R., Salonen J.T. 2004 Testosterone and sex hormone-binding globulin predict the metabolic syndrome and diabetes in middle-aged men. Diabetes Care 27:1036-1041 (Pubitemid 38579762)
29. Lakshman K.M., Bhasin S., Araujo A.B. 2010 Sex hormone-binding globulin as an independent predictor of incident type 2 diabetes mellitus in men. J Gerontol A Biol Sci Med Sci 65:503-509
30. Ding E.L., Song Y., Manson J.E., Hunter D.J., Lee C.C., Rifai N., Buring J.E., Gaziano J.M., Liu S. 2009 Sex hormone-binding globulin and risk of type 2 diabetes in women and men.NEngl JMed361:1152-1163
31. Perry J.R., Weedon M.N., Langenberg C., Jackson A.U., Lyssenko V., Sparsø T., Thorleifsson G., Grallert H., Ferrucci L., Maggio M., Paolisso G., Walker M., Palmer C.N., Payne F., Young E., Herder C., Narisu N., Morken M.A., Bonnycastle L.L., Owen K.R., Shields B., Knight B., Bennett A., Groves C.J., Ruokonen A., JarvelinM.R.,Pearson E., Pascoe L., Ferrannini E., Bornstein S.R., Stringham H.M., Scott L.J., Kuusisto J., Nilsson P., Neptin M., Gjesing A.P., Pisinger C., Lauritzen T., Sandbaek A., Sampson M., Zeggini E., Lindgren C.M., Steinthorsdottir V., Thorsteinsdottir U., Hansen T., Schwarz P., Illig T., Laakso M., Stefansson K., Morris A.D., Groop L., Pedersen O., Boehnke M., Barroso I., Wareham N.J., Hattersley A.T., McCarthy M.I., Frayling T.M. 2010 Genetic evidence that raised sex hormone binding globulin (SHBG) levels reduce the risk of type 2 diabetes. Hum Mol Genet 19:535-544
32. Behrend L., Vibe-Petersen J., Perrild H. 2005 Sildenafil in the treatment of erectile dysfunction in men with diabetes: Demand, efficacy and patient satisfaction. Int J Impot Res 17:264-269 (Pubitemid 40675510)
33. Laughlin G.A., Barrett-Connor E., Bergstrom J. 2008 Low serum testosterone and mortality in older men. J Clin Endocrinol Metab 93: 68-75
34. Tivesten A., Vandenput L., Labrie F., Karlsson M.K., Ljunggren O., Mellström D., Ohlsson C. 2009 Low serum testosterone and estradiol predict mortality in elderly men. J Clin Endocrinol Metab 94:2482-2488
35. Yeap B.B., Hyde Z., Almeida O.P., Norman P.E., Chubb S.A., Jamrozik K., Flicker L., Hankey G.J. 2009 Lower testosterone levels predict incident stroke and transient ischemic attack in older men. J Clin Endocrinol Metab 94:2353-2359
36. Khaw K.T., Dowsett M., Folkerd E., Bingham S., Wareham N., Luben R., Welch A., Day N. 2007 Endogenous testosterone and mortality due to all causes, cardiovascular disease, and cancer in men: European Prospective Investigation into Cancer in Norfolk (EPIC-Norfolk) Prospective Population Study. Circulation 116:2694-2701 (Pubitemid 350291241)
37. Vikan T., Johnsen S.H., Schirmer H., Njølstad I., Svartberg J. 2009 Endogenous testosterone and the prospective association with carotid atherosclerosis in men: The Tromso study. Eur J Epidemiol 24:289-295
38. Shores M.M., Matsumoto A.M., Sloan K.L., Kivlahan D.R. 2006 Low serum testosterone and mortality in male veterans. Arch Intern Med 166:1660-1665 (Pubitemid 44232378)
39. Araujo A.B., Kupelian V., Page S.T., Handelsman D.J., Bremner W.J., McKinlay J.B. 2007 Sex steroids and all-cause and cause-specific mortality in men. Arch Intern Med 167:1252-1260 (Pubitemid 46998496)
40. Smith G.D., Ben-Shlomo Y., Beswick A., Yarnell J., Lightman S., Elwood P. 2005 Cortisol, testosterone, and coronary heart disease: Prospective evidence from the Caerphilly study. Circulation 112: 332-340 (Pubitemid 41022073)
41. Malkin C.J., Pugh P.J., Morris P.D., Asif S., Jones T.H., Channer K.S. 2010 Low serum testosterone and increased mortality in men with coronary heart disease. Heart 96:1821-1825
42. Ponikowska B., Jankowska E.A., Maj J., Wegrzynowska-Teodorczyk K., Biel B., Reczuch K., Borodulin-Nadzieja L., Banasiak W., Ponikowski P. 2010 Gonadal and adrenal androgen deficiencies as independent predictors of increased cardiovascular mortality in men with type II diabetes mellitus and stable coronary artery disease. Int J Cardiol 143:343-348
43. Dhindsa S., Bhatia V., Dhindsa G., Chaudhuri A., Gollapudi G.M., Dandona P. 2007 The effects of hypogonadism on body composition and bone mineral density in type 2 diabetic patients. Diabetes Care 30:1860-1861 (Pubitemid 47036365)
44. Traish A.M., Saad F., Feeley R.J., Guay A. 2009 The dark side of testosterone deficiency. III. Cardiovascular disease. J Androl 30:477-494
45. Dandona P., Dhindsa S., Chaudhuri A., Bhatia V., Topiwala S., Mohanty P. 2008 Hypogonadotrophic hypogonadism in type 2 diabetes, obesity and the metabolic syndrome. Curr Mol Med 8:816-828
46. Grossmann M., Panagiotopolous S., Sharpe K., MacIsaac R.J., Clarke S., Zajac J.D., Jerums G., Thomas M.C. 2009 Low testosterone and anaemia in men with type 2 diabetes. Clin Endocrinol (Oxf) 70: 547-553
47. Shahidi N.T. 1973 Androgens and erythropoiesis. N Engl J Med 289:72-80
48. Orwoll E.S., Klein R.F. 1995 Osteoporosis in men. Endocr Rev 16: 87-116
49. Jackson J.A., Riggs M.W., Spiekerman A.M. 1992 Testosterone deficiency as a risk factor for hip fractures in men: A case-control study. Am J Med Sci 304:4-8
50. Benito M., Gomberg B., Wehrli F.W., Weening R.H., Zemel B., Wright A.C., Song H.K., Cucchiara A., Snyder P.J. 2003 Deterioration of trabecular architecture in hypogonadal men. J Clin Endocrinol Metab 88:1497-1502 (Pubitemid 36623360)
51. Khosla S., Melton 3rd L.J., Atkinson E.J., O'Fallon W.M., Klee G.G., Riggs B.L. 1998 Relationship of serum sex steroid levels and bone turnover markers with bone mineral density in men and women: A key role for bioavailable estrogen. J Clin Endocrinol Metab 83: 2266-2274 (Pubitemid 28503012)
52. Mellström D., Johnell O., Ljunggren O., Eriksson A.L., Lorentzon M., Mallmin H., Holmberg A., Redlund-Johnell I., Orwoll E., Ohlsson C. 2006 Free testosterone is an independent predictor of BMD and prevalent fractures in elderly men: MrOS Sweden. J Bone Miner Res 21:529-535
53. Lorentzon M., Swanson C., Andersson N., Mellström D., Ohlsson C. 2005 Free testosterone is a positive, whereas free estradiol is a negative, predictor of cortical bone size in young Swedish men: The GOOD study. J Bone Miner Res 20:1334-1341 (Pubitemid 41033517)
54. Vasilkova O., Mokhort T., Sanec I., Sharshakova T., Hayashida N., Takamura N. 2011 Testosterone is an independent determinant of bone mineral density in men with type 2 diabetes mellitus. Clin Chem Lab Med 49:99-103
55. Werny D.M., Saraiya M., Gregg E.W. 2006 Prostate-specific antigen values in diabetic and nondiabetic US men, 2001-2002. Am J Epidemiol 164:978-983 (Pubitemid 44729839)
56. Dhindsa S., Upadhyay M., Viswanathan P., Howard S., Chaudhuri A., Dandona P. 2008 Relationship of prostate-specific antigen to age and testosterone in men with type 2 diabetes mellitus. Endocr Pract 14: 1000-1005
57. Inoue M., Iwasaki M., Otani T., Sasazuki S., Noda M., Tsugane S. 2006 Diabetes mellitus and the risk of cancer: Results from a large-scale population-based cohort study in Japan. Arch Intern Med 166: 1871-1877 (Pubitemid 44455170)
58. Heikkilä R., Aho K., Heliövaara M., Hakama M., Marniemi J., Reunanen A., Knekt P. 1999 Serum testosterone and sex hormone-binding globulin concentrations and the risk of prostate carcinoma: A longitudinal study. Cancer 86:312-315 (Pubitemid 29327588)
59. Kapoor D., Goodwin E., Channer K.S., Jones T.H. 2006 Testosterone replacement therapy improves insulin resistance, glycaemic control, visceral adiposity and hypercholesterolaemia in hypogonadal men with type 2 diabetes. Eur J Endocrinol 154:899-906 (Pubitemid 43997730)
60. Heufelder A.E., Saad F., Bunck M.C., Gooren L. 2009 Fifty-two-week treatment with diet and exercise plus transdermal testosterone reverses the metabolic syndrome and improves glycemic control in men with newly diagnosed type 2 diabetes and subnormal plasma testosterone. J Androl 30:726-733
61. Jones T.H., Arver S., Behre H.M., Buvat J., Meuleman E., Moncada I., Morales A.M., Volterrani M., Yellowlees A., Howell J.D., Channer K.S. 2011 Testosterone replacement in hypogonadal men with type 2 diabetes and/or metabolic syndrome (the TIMES2 Study). Diabetes Care 34:828-837
62. Lee C.H., Kuo S.W., Hung Y.J., Hsieh C.H., He C.T., Yang T.C., Lian W.C., Chyi-Fan S., Pei D. 2005 The effect of testosterone supplement on insulin sensitivity, glucose effectiveness, and acute insulin response after glucose load in male type 2 diabetics. Endocr Res 31:139-148 (Pubitemid 41759228)
63. Buvat J., Montorsi F., Maggi M., Porst H., Kaipia A., Colson M.H., Cuzin B., Moncada I., Martin-Morales A., Yassin A., Meuleman E., Eardley I., Dean J.D., Shabsigh R. 2011 Hypogonadal men nonresponders to the PDE5 inhibitor tadalafil benefit from normalization of testosterone levels with a 1% hydroalcoholic testosterone gel in the treatment of erectile dysfunction (TADTEST study). J Sex Med 8:284-293
64. Fernández-Balsells M.M., Murad M.H., Lane M., Lampropulos J.F., Albuquerque F., Mullan R.J., Agrwal N., Elamin M.B., Gallegos-Orozco J.F., Wang A.T., Erwin P.J., Bhasin S., Montori V.M. 2010 Clinical review 1: Adverse effects of testosterone therapy in adult men: A systematic review and meta-analysis. J Clin Endocrinol Metab 95: 2560-2575
65. Basaria S., Coviello A.D., Travison TG, StorerTW,FarwellWR,Jette AM, Eder R, Tennstedt S, Ulloor J, Zhang A, Choong K, Lakshman KM, Mazer NA, Miciek R, Krasnoff J, Elmi A, Knapp PE, Brooks B, Appleman E, Aggarwal S, Bhasin G, Hede-Brierley L, Bhatia A, Collins L, LeBrasseur N, Fiore LD, Bhasin S 2010 Adverse events associated with testosterone administration. N Engl J Med 363: 109-122
66. Srinivas-Shankar U., Roberts S.A., Connolly M.J., O'Connell M.D., Adams J.E., Oldham J.A., Wu F.C. 2010 Effects of testosterone on muscle strength, physical function, body composition, and quality of life in intermediate-frail and frail elderly men: A randomized, double-blind, placebo-controlled study. J Clin Endocrinol Metab 95:639-650
67. Page S.T., Amory J.K., Bowman F.D., Anawalt B.D., Matsumoto A.M., Bremner W.J., Tenover J.L. 2005 Exogenous testosterone (T) alone or with finasteride increases physical performance, grip strength, and lean body mass in older men with low serum T. J Clin Endocrinol Metab 90:1502-1510 (Pubitemid 40464011)
68. Nair K.S., Rizza R.A., O'Brien P., Dhatariya K., Short K.R., Nehra A., Vittone J.L., Klee G.G., Basu A., Basu R., Cobelli C., Toffolo G., Dalla Man C., Tindall D.J., Melton 3rd L.J., Smith G.E., Khosla S., JensenM.D. 2006 DHEA in elderly women and DHEA or testosterone in elderly men. N Engl J Med 355:1647-1659 (Pubitemid 44583955)
69. Muraleedharan V., Marsh H., Jones H, Low testosterone predicts increased mortality and testosterone replacement therapy improves survival in men with type 2 diabetes. Proc Meeting of the British Endocrine Societies/Society for Endocrinology, Birmingham, UK, 2011 (Abstract 25 P163)
70. Caminiti G., Volterrani M., Iellamo F., Marazzi G., Massaro R., Miceli M., Mammi C., Piepoli M., Fini M., Rosano G.M. 2009 Effect of longacting testosterone treatment on functional exercise capacity, skeletal muscle performance, insulin resistance, and baroreflex sensitivity in elderly patients with chronic heart failure: A double-blind, placebo-controlled, randomized study. J Am Coll Cardiol 54:919-927
71. Kapoor D., Clarke S., Stanworth R., Channer K.S., Jones T.H. 2007 The effect of testosterone replacement therapy on adipocytokines and C-reactive protein in hypogonadal men with type 2 diabetes. Eur J Endocrinol 156:595-602 (Pubitemid 46796527)